When does this change take effect?

This change is effective Apr 1, 2026.

CommercialCoverageMedium impact

08.01.47a, Triamcinolone Acetonide Extended-Release Injectable (Zilretta®)

Q: Who is affected by this change?

This affects Independence Blue Cross Orthopedics, Rheumatology, Pain Management, PM&R (Physical Medicine & Rehab) providers on Commercial plans.

Independence Blue Cross·Orthopedics, Rheumatology, Pain Management +1 more·Pharmacy

Effective date

Apr 1, 2026

We identified it

Jun 19, 2026

Days to comply

—

Summary

The policy for Triamcinolone Acetonide Extended-Release Injectable (Zilretta®) has been reissued with an effective date of April 1, 2026. This is a pharmacy policy update for the extended-release injectable medication used primarily for osteoarthritis pain management.

Action Required

Action needed

By April 1, 2026: Review the updated Zilretta® policy at the provided URL to understand any changes to coverage criteria, prior authorization requirements, or billing guidelines. Update any internal protocols and inform providers who prescribe this extended-release injectable for osteoarthritis treatment.

Related policy hubs

Independence Blue Cross policies Orthopedics Rheumatology Pain Management PM&R (Physical Medicine & Rehab)